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Abstract
Background: To examine whether augmentation index (AIx) is increased in Marfan syndrome
(MFS) and associated with increased aortic root size, and whether a peripheral-to-central
generalised transfer function (GTF) can be applied usefully in MFS.
Methods: 10 MFS patients and 10 healthy controls (matched for sex, age and height) were studied
before and after 400 μg sub-lingual GTN. Arterial waveforms were recorded using applanation
tonometry. AIx and pulse pressure (PP) were determined for the radial and carotid arteries. Pulse
wave velocity (PWV) was measured between carotid and femoral arteries. GTFs were generated
to examine the relationship between radial and carotid waveforms.
Results: AIx was greater in MFS compared to controls at radial (mean -31.4 (SD 14.3)% v -
50.2(15.6)%, p = 0.003) and carotid (-7.6(11.2)% v -23.7(12.7)%, p = 0.004) sites. Baseline PP at all
measurement sites, and PWV, did not differ between subject groups. Multivariate analysis
demonstrated that PWV and carotid AIx were positively correlated with aortic root size (p < 0.001
and p = 0.012 respectively), independent of the presence of MFS. PP was not associated with aortic
root size. GTN caused similar decreases in AIx in both controls and patients. Significant differences
were found in GTFs between MFS and control subjects, which changed following GTN
administration. However, when an independent GTF was used to derive carotid waves from radial
waves, no differences were found in the degree of error between MFS and controls.
Conclusion: AIx is sensitive to the vascular abnormalities present in MFS, and may have a role as
an adjunct to measurement of central PP and PWV. Differences between MFS and controls in the
nature of the peripheral-to-central GTF are present, although have little effect on the pulse
contour.
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Background
Marfan syndrome (MFS) is an autosomal dominant con-
nective tissue disorder due to mutations in the fibrillin 1
gene[1,2]. It results in impairment of protein to protein
interactions in the extracellular matrix[3], affecting many
systems, but in particular manifesting as typical skeletal,
ocular, and cardiovascular features[4]. The latter includes
aortic root dilatation, with the associated problems of aor-
tic incompetence, dissection and rupture. These complica-
tions are the major cause of morbidity and premature
death in this condition[5], and necessitate regular follow-
up to monitor changes in aortic root size[6,7].
The mechanisms leading to aortic dilatation remain
uncertain. The load-bearing capacity of the aortic wall
may be compromised due to abnormal elastic fibres and
impaired elastin cross-linking[5,8]. Indeed, increased cen-
tral arterial stiffness has been shown to be associated with
increased aortic diameter in MFS[9,10]. The problem
might be further aggravated by increased central pulsatile
stress[11], which may be attributable to altered pulse
wave reflections. Arterial wall stiffness determines the
nature of propagation of pressure waves, by affecting both
the pulse wave velocity (PWV) and the magnitude of
reflections at peripheral sites of impedance mismatch[12].
Reflected waves can be quantified in terms of the degree
to which they augment the incident pressure wave as a
proportion of the pulse pressure. The difference in pres-
sure between reflected and incident waves, as a percentage
of pulse pressure, is known as augmentation index (AIx).
AIx can be determined either centrally or peripherally, and
reflects underlying arterial stiffness[13]. Central pressure
measurement can be carried out non-invasively at the
carotid artery, but can also be estimated from peripheral
measurements by application of a transfer function. A
transfer function is a mathematical description of the rela-
tionship between frequency components of a pulsatile
phenomenon (e.g. arterial pressure wave) measured at
two locations, and is widely used in engineering sciences.
Pulse waveform analysis may have a potential role in
assessment of patients with MFS. The objectives of the
present study were, firstly, to determine if AIx is increased
in MFS, and associated with an increase in aortic root size;
and secondly, to determine whether the transfer function
differs between healthy individuals and subjects with
MFS, and whether it is influenced by pharmacologically-
induced haemodynamic disturbances.
Methods
Ten MFS patients (7 male), aged 16 to 48 years, were stud-
ied. Patients were strictly defined according to the Gent
criteria[4]. Beta-blockers and other cardiac medications
were stopped for 48 hours prior to the study. The normal
control group (N = 10) was matched one-to-one for age,
sex and height. Written informed consent was obtained
from all subjects. The study had Local Research Ethics
Committee approval, and was conducted in accordance
with the principles of the Declaration of Helsinki.
All studies were carried out in a quiet, temperature con-
trolled environment. After a 30 minute rest period, meas-
urements were made of blood pressure and arterial
stiffness before, and 5 minutes after, administration of
400 μg sub-lingual glyceryl trinitrate (GTN).
Arterial waveforms were recorded non-invasively over 10s
using a high-fidelity hand-held tonometer (SPT-301, Mil-
lar Instruments)[14]. Aortic pulse wave velocity was
recorded by making sequential ECG-gated tonometer
recordings at the carotid and femoral arteries. The
straight-line distances between the sternal-notch and both
waveform measurement sites was determined, and path
length taken as the difference between the two distances.
Pulse wave contour analysis was performed by making
further recordings at both radial and carotid arteries. The
radial pressure wave was calibrated to brachial blood pres-
sure (Omron 705CP). The carotid waveform was cali-
brated assuming mean and diastolic pressure at brachial
and carotid sites to be equal[15]. Pulse contour analysis
was performed on ensemble-averaged waves. AIx was cal-
culated from the formula AIx = 100 × ((P2-P1)/PP), where
P1 and P2 are the first and second systolic pressure peaks
respectively, and PP is the pulse pressure. Wave inflection
points were determined using an automated algorithm to
identify the zero-crossing points of the fourth-derivative,
as previously described[16]. The maximal slope (dP/
dtMAX) of the pulse wave leading edge was also recorded,
as this can be affected by valvular dysfunction[17]. Signal
processing and analysis was performed blinded to clinical
data.
Transfer functions were calculated by Fourier transform,
to describe the frequency-dependent change in gain and
phase between radial and carotid waveforms. This was
done for MFS and control subjects, both before and after
GTN administration, with signals synchronised at the
maximum slope. Generalised transfer functions (GTFs)
were computed by averaging the relevant individualised
transfer functions for each subject over 0 to 10 Hz. GTFs
were compared by examining the area under the curve
(AUC) and the lowest frequency at which a minimum
occurred for both gain and phase. In order to determine
whether differences in GTFs might result in discrepancies
in the estimation of central haemodynamic parameters,
actual carotid measurements were compared with those
derived from the radial waveform using an independently
generated radial-to-carotid GTF. This was constructed by
combining the radial-to-aortic and aortic-to-carotid GTFsJournal of Cardiothoracic Surgery 2007, 2:43 http://www.cardiothoracicsurgery.org/content/2/1/43
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employed by the commercially available SphygmoCor
system (AtCor Medical).
Echocardiograph examination was performed by an expe-
rienced cardiac technician according to standard local pol-
icy, using a Philips ATL5000 system. Aortic root diameter
was measured at end-systole in the parasternal long-axis
view, at the levels of the sinus of Valsalva and the sinotu-
bular junction. We found measurement site had little
effect on our overall findings, and so have reported only
results for the former.
Differences between subject groups, changes with GTN,
and discrepancies between actual and derived waves, were
evaluated using paired non-parametric (Wilcoxon signed
rank test) and parametric (paired t-test) comparisons as
appropriate. Multivariate analysis was used to establish
the determinants of carotid AIx, PWV and aortic root size.
Statistical significance was taken as p < 0.05. Analysis was
carried out using SPSS v12.0 (SPSS Inc., Illinois).
Results
The two groups were well matched for age, sex, smoking
status, height and body mass index (Table 1). Aortic root
size was significantly greater in the Marfan subjects. Trivial
aortic regurgitation was observed in 4 MFS subjects and 1
control (p = 0.38), and trivial mitral regurgitation in 7
MFS subjects and 3 controls, (p = 0.13).
Baseline haemodynamic parameters (Table 2) demon-
strated no differences in resting heart rate, brachial systo-
lic or diastolic blood pressure, or mean arterial pressure.
Baseline brachial and carotid pulse pressure were not dif-
ferent between the two groups. dP/dtMAX was not found to
be significantly different between controls and MFS sub-
jects when measured at either the carotid (p = 0.10) or
radial artery (p = 0.27). Multivariate analysis was per-
formed to ascertain the principal determinants of carotid
AIx and PWV (Table 3). MFS was the strongest independ-
ent determinant of variation in carotid AIx, followed by
age and height. Age and mean arterial pressure were the
strongest independent determinants of PWV, although
the presence of MFS nonetheless had an independent
(albeit weak) association. Multivariate analysis revealed
that both aortic PWV and baseline carotid AIx were posi-
tively correlated with aortic root size (Table 3, Figure 1),
independent of the presence or absence of MFS, although
this was not evident if aortic root size was corrected for
body surface area. Age, sex, mean arterial pressure and
carotid pulse pressure were not significantly associated
with aortic root size.
GTN caused a decrease in AIx measured at both sites in
both subject groups (Table 4), but there were no signifi-
cant differences in the degree of change between MFS sub-
jects and controls. No significant differences were found
in the responses of blood pressure, heart rate or PWV to
GTN in either group.
Generalised transfer functions for baseline and post-GTN
for both MFS and control subjects are shown in Figure 2.
Before GTN, there were no significant differences between
MFS and control in the lowest-frequencies at which the
maximum negative phase shift occurred (2.2 ± 0.5 Hz vs.
2.0 ± 0.6 Hz respectively, p = 0.45) and greatest decrease
in gain occurred (2.9 ± 0.9 Hz vs. 3.3 ± 1.1 Hz respectively,
p = 0.41), or in AUC for gain (10.5 ± 3.1 vs. 8.1 ± 1.6
units.Hz, p = 0.09). Similar findings were observed after
GTN. The AUC for phase was more negative for MFS than
controls (-2.6 ± 2.1 vs. -0.8 ± 1.8 radians.Hz, p = 0.042)
before GTN, although no significant differences were
observed between subject groups after GTN. Following
GTN administration, the lowest-frequency at which the
maximum negative phase shift occurred decreased to 1.5
± 0.4 in controls (p = 0.004) and 1.7 ± 0.5 in MFS (p =
0.001). The frequency at which the greatest decrease in
gain occurred fell to 2.6 ± 0.4 Hz in controls (p = 0.017),
and non-significantly in MFS (2.5 ± 0.7 Hz, p = 0.18).
GTN had no significant effect on the gain or phase AUC
for either controls or MFS.
Table 1: Subject characteristics
Control (n = 10) MFS (n = 10) P value
Age, years 26.9 (7.2) 26.4 (11.6) NS
Male, n 7 (70%) 7 (70%) NS
Smokers, n 3 (30%) 1 (9%) NS
Height, cm 187.1 (9.7) 188.9 (10.2) NS
BMI, kg/m2 24.0 (3.9) 22.1 (3.7) NS
Aortic root size, mm SV 30.7 (3.6) 41.8 (4.2) <0.0001
STJ 30.7 (4.3) 39.7 (6.1) <0.001
Aortic root (BSA adjusted) SV 14.7 (0.6) 20.7 (2.5) <0.0001
STJ 14.7 (1.0) 19.7 (3.4) <0.001
Values are mean (SD) or number (%). BMI, body mass index. BSA, body surface area. SV, sinus of Valsalva. STJ, sinotubular junction.Journal of Cardiothoracic Surgery 2007, 2:43 http://www.cardiothoracicsurgery.org/content/2/1/43
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When an independently generated GTF was applied to the
radial waveforms, carotid AIx was underestimated both
before (-5.9 ± 1.9%, p = 0.005) and after (-6.5 ± 3.5%, p
= 0.081) GTN administration. There was no significant
bias in the estimation of carotid pulse pressure or systolic
BP either before (-1.7 ± 1.0 mmHg, p = 0.10; 0.9 ± 0.9
mmHg, p = 0.34 respectively) or after (0.01 ± 1.4 mmHg,
p = 0.99; -0.9 ± 1.3 mmHg, p = 0.50) GTN. No significant
differences existed in the degree of bias between MFS and
control subjects, either before GTN (AIx, -2.0 ± 2.1%, p =
0.36; pulse pressure, -0.8 ± 1.3 mmHg, p = 0.56; systolic
BP, -0.7 ± 1.2 mmHg, p = 0.57) or after GTN (AIx, -2.6 ±
4.8%, p = 0.61; pulse pressure, -4.2 ± 2.3, p = 0.10; systolic
BP, -3.9 ± 2.2 mmHg, p = 0.12).
Discussion
This study found that carotid AIx was increased in MFS,
and had a weak positive association with aortic root size,
independent of PWV. There were no differences observed
in pulse pressure, regardless of measurement site, between
subject groups, and pulse pressure was not related to aor-
tic root size. The transfer function describing the relation-
ship between peripheral and central waveforms differed
slightly between healthy subjects and patients with MFS,
and was altered in both groups by the administration of
GTN. However, these variations in transfer function had
minimal effect on the mean error in derived central
haemodynamic measures.
Arterial stiffness determines the velocity of pressure wave
propagation in the arterial tree, and therefore also the
nature of pressure wave reflections. Reflected waves aug-
ment proximal aortic pressure, thus affecting cardiac work
and myocardial perfusion, as well as influencing central
pulse pressure. Arterial stiffness, pulse wave velocity and
pulse pressure are therefore inextricably linked. It has pre-
viously been shown that central pulse pressure, but not
peripheral pulse pressure or mean pressure, is associated
with increased aortic root size in MFS[11]. These findings
have been attributed to increased pressure augmentation
by reflected waves, which in turn leads to increased cycli-
Table 2: Baseline haemodynamic parameters
Control (n = 10) MFS (n = 10) P value
Brachial BP, mmHg 120/68 (12/8) 114/64 (15/8) NS
Heart rate, bpm 63 (14) 59 (11) NS
Mean arterial pressure, mmHg 84 (10) 81 (11) NS
Pulse pressure, mmHg Brachial 51.5 (8.0) 49.5 (9.8) NS
Carotid 39.7 (8.5) 40.0 (9.3) NS
dP/dtMAX, mmHg/s Radial 645 (120) 572 (120) NS
Carotid 772 (229) 606 (143) NS
Augmentation index, % Radial -50.2 (15.6) -31.4 (14.3) 0.003
Carotid -23.7 (12.7) -7.6 (11.2) 0.004
Aortic pulse wave velocity, m/s 5.8 (1.2) 6.6 (1.7) NS
Values are mean (SD)
Table 3: Multivariate analysis of determinants of augmentation index, pulse wave velocity and aortic root size
Dependent variable Independent variable R-square Standardised β-coefficient p
Carotid AIx
Presence of MFS 0.34 -0.63 <0.001
Age 0.66 -0.57 <0.001
Height 0.81 0.40 0.002
PWV
Age 0.50 0.47 0.007
MAP 0.61 0.47 0.008
Presence of MFS 0.72 0.34 0.022
Aortic root size
Presence of MFS 0.69 0.90 <0.001
PWV 0.82 0.50 <0.001
Carotid AIx 0.88 0.33 0.012
Aortic root/BSA
Presence of MFS 0.76 0.87 <0.001
AIx, augmentation index. MAP, mean arterial pressure. PWV, pulse wave velocity. MFS, Marfan Syndrome. Aortic root size is at sinus of Valsalva. 
BSA is adjustment for body surface area.Journal of Cardiothoracic Surgery 2007, 2:43 http://www.cardiothoracicsurgery.org/content/2/1/43
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cal stress in the aorta and, subsequently, structural weak-
ness and aortic root dilatation.
Pulse wave velocity was increased in our patient group.
The lack of significance is probably explained by insuffi-
cient statistical power. Patients with MFS have increased
arterial stiffness due to altered elastin fibres. Our findings
are similar to those of Jeremy et al[10] using echocardiog-
raphy, and Groenink et al[7] using MRI, who have both
shown aortic PWV to be increased in MFS by approxi-
mately 2.3 m/s relative to controls. The smaller difference
seen in the current study may be due to the different meth-
odology employed in the measurement of PWV. AIx was
greater in the MFS group than the control group. This dif-
ference was highly significant, compared to the difference
in PWV, and suggests that AIx may be a more sensitive
marker than PWV for the presence of MFS. It is, therefore,
also possible that differences in impedance mismatch in
peripheral vessels between the two groups, rather than
simply large artery stiffness, may contribute to the eleva-
tion of AIx observed in MFS patients. Furthermore,
although AIx is dependent on the nature of ventricular
ejection, it appears improbable that this would account
for the differences in AIx observed between the two
groups: firstly, the degree of valvular regurgitation found
on echocardiography was trivial, and unlikely to be
haemodynamically significant; secondly, the slight excess
of aortic regurgitation in the MFS group would, in contrast
to the present findings, be expected to decrease AIx and
increase  dP/dtMAX relative to controls[17]. It is possible
that although beta-blockade was stopped in the MFS
group, residual effects from these drugs might have con-
tributed to the increase in AIx. Although it is difficult to
entirely discount this possibility, the lack of significant
difference in either heart rate or dP/dtMAX between the two
groups does not support this argument. It seems most
likely that vascular rather than cardiac differences account
for the increase in AIx in MFS observed in this study. Inter-
estingly, previous work by Segers et al failed to show a sig-
nificant difference in AIx between MFS and controls[18] –
this may have been due to differences in height between
the two groups, and possibly differences in methodology.
Previous groups have also shown endothelial function to
be impaired in peripheral vessels in MFS[19], but no data
have been hitherto available on endothelium-independ-
ent arterial reactivity. We had expected to see a less
marked response to GTN in the MFS group, due to struc-
tural arterial differences resulting in impaired endothe-
lium-independent vaso-relaxation. Our findings suggest
that there is no difference in the non-endothelium
dependent vascular reactivity of MFS patients.
Importantly, the difference in AIx did not correspond with
a difference in pulse pressure. Furthermore, AIx and PWV
were associated with aortic root size, whereas pulse pres-
sure was not. This might suggest that, rather than elevated
AIx and central pulse pressure being causal in the develop-
ment of aortic dilatation, increased AIx may simply be a
manifestation of structural abnormalities and weakness
that exist in the aortic wall of MFS patients, and it is these
structural changes which directly lead to aortic dilatation.
Despite this, it is not possible to exclude an influence of
central pulse pressure upon aortic root diameter, as dem-
onstrated by others[11], because the number of patients
Table 4: Change from baseline haemodynamic values in response to GTN
Control (n = 10) MFS (n = 10)
Mean change p Mean change p
Heart rate, bpm 0.6 (3.6) NS 2.7 (6.1) NS
Mean arterial pressure, mmHg -7.0 (5.3) 0.002 -4.1 (8.4) NS
Pulse pressure, mmHg Brachial 0.5 (9.4) NS 5.1 (8.2) NS
Carotid 0.4 (10.1) NS 1.1 (6.0) NS
Augmentation index, % Radial -14.7 (13.1) 0.006 -21.8 (12.1) 0.0003
Carotid -8.7 (8.2) 0.008 -10.8 (10.8) 0.011
Aortic pulse wave velocity, m/s -0.1 (0.5) NS 0.1 (0.5) NS
Values are mean (SD)
Correlation between aortic root size and haemodynamic  measures Figure 1
Correlation between aortic root size and haemody-
namic measures. Black circles, Marfan syndrome patients; 
white circles, controls. Aortic root measurements are those 
at sinus of Valsalva, not adjusted for body surface area. AIx, 
augmentation index.
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in this study was rather small. Nonetheless, AIx may be a
more robust marker of the presence of MFS than central
pulse pressure, as it can be measured directly, without
relying on assumptions about the constancy of mean and
diastolic pressure between arterial sites.
Generalised transfer functions are increasingly used to
estimate central pressure from peripheral measurements,
but have not been validated in patients with MFS. We
used carotid pressure as a surrogate for central pressure,
and found subtle differences in GTF between MFS patients
and controls. The GTF was similarly altered in both sub-
ject groups following haemodynamic disturbance with
GTN. Nonetheless, the use of a transfer function generated
independently of the current study, resulted in similar
accuracy in both controls and MFS subjects. Although
invasive aortic measurements would have been more val-
uable, they are difficult to ethically justify in any persons
other than those undergoing preoperative cardiac cathe-
terisation. Caution should be taken before extending
these findings to support the argument for the use of a
radial-to-aortic GTF for estimating central pressure from
peripheral measurements in MFS patients. Furthermore, it
remains to be seen whether central AIx might provide any
particular advantage over peripheral AIx with regards to
prediction of disease progression.
The main limitation of this study is that it was quite small.
Unfortunately, this is due to the difficulties of recruiting
patients with this condition for research work. This may
explain the small differences in central pulse pressure and
PWV between the two groups. Regardless of this, AIx was
clearly elevated in the MFS population, and would appear
to reflect differences in vascular properties in these
patients.
Conclusion
This study suggests that AIx, a value which can be quickly
and directly determined in a clinical setting, may be more
sensitive to the presence of MFS than PWV or central pulse
pressure alone. Importantly, however, it must be remem-
bered that these parameters are closely inter-related, and
AIx should be considered an adjunct rather than alterna-
tive to PWV and pulse pressure. Subtle differences in the
MFS transfer function exist, and although these appear to
have little effect on the estimation of central haemody-
namic parameters, caution should be exhibited in the
application of GTFs not generated from this patient pop-
ulation. Additional work is justified to establish whether
AIx and the use of GTFs have clinical utility both in the
evaluation of the risk of cardiovascular complications in
MFS, or for monitoring disease progression.
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